Preoperative blood-routine markers and prognosis of esophageal squamous cell carcinoma: The Fujian prospective investigation of cancer (FIESTA) study

Hu, Dan; Lin, Xiaoxiao; Chen, Yan; Chang, Qing; Chen, Gang; Li, Chao; Zhang, Hejun; Cui, Zhaolei; Liang, Binying; Jiang, Wenhui; Ji, Kaida; Huang, Jun; Peng, Feng; Xiao, Zheng; Niu, Wenquan

doi:10.18632/oncotarget.13318

Cited by 25 publications

(27 citation statements)

References 47 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The FIESTA study initiated in January 2000 is an ongoing prospective cohort study of common digestive system tumors, including esophageal cancer, gastric cancer and colorectal cancer (Hu et al, 2016a, Peng et al, 2016, Hu et al, 2016b), and the purport of this study is to identify preoperative prognostic risk factors for cancer-specific mortality, which will help pinpoint underlying targets to delay tumor progression and prolong the survival of cancer patients after surgery. The conduct of this FIESTA study was approved by the Ethics Committee of Fujian Provincial Cancer Hospital and informed consent was obtained from all participants.…”

Section: Methodsmentioning

confidence: 99%

Preoperative Metabolic Syndrome Is Predictive of Significant Gastric Cancer Mortality after Gastrectomy: The Fujian Prospective Investigation of Cancer (FIESTA) Study

Peng

Lin

et al. 2017

EBioMedicine

Self Cite

View full text Add to dashboard Cite

Metabolic syndrome (MetS) has been shown to be associated with an increased risk of gastric cancer. However, the impact of MetS on gastric cancer mortality remains largely unknown. Here, we prospectively examined the prediction of preoperative MetS for gastric cancer mortality by analyzing a subset of data from the ongoing Fujian prospective investigation of cancer (FIESTA) study. This study was conducted among 3012 patients with gastric cancer who received radical gastrectomy between 2000 and 2010. The latest follow-up was completed in 2015. Blood/tissue specimens, demographic and clinicopathologic characteristics were collected at baseline. During 15-year follow-up, 1331 of 3012 patients died of gastric cancer. The median survival time (MST) of patients with MetS was 31.3 months, which was significantly shorter than that of MetS-free patients (157.1 months). The coexistence of MetS before surgery was associated with a 2.3-fold increased risk for gastric cancer mortality (P < 0.001). The multivariate-adjusted hazard ratios (HRs) were increased with invasion depth T1/T2 (HR = 2.78, P < 0.001), regional lymph node metastasis N0 (HR = 2.65, P < 0.001), positive distant metastasis (HR = 2.53, P < 0.001), TNM stage I/II (HR = 3.00, P < 0.001), intestinal type (HR = 2.96, P < 0.001), negative tumor embolus (HR = 2.34, P < 0.001), and tumor size ≤ 4.5 cm (HR = 2.49, P < 0.001). Further survival tree analysis confirmed the top splitting role of TNM stage, followed by MetS or hyperglycemia with remarkable discrimination ability. In this large cohort study, preoperative MetS, especially hyperglycemia, was predictive of significant gastric cancer mortality in patients with radical gastrectomy, especially for early stage of gastric cancer.

show abstract

Section: Methodsmentioning

confidence: 99%

Preoperative Metabolic Syndrome Is Predictive of Significant Gastric Cancer Mortality after Gastrectomy: The Fujian Prospective Investigation of Cancer (FIESTA) Study

Peng

Lin

et al. 2017

EBioMedicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…To avoid duplicate counting, only one study with more complete data was selected [ 15 ]. Therefore, 16 studies (17 cohorts) with a total of 6699 patients published between 2011 and 2017 were finally enrolled in our meta-analysis [ 13 - 16 , 19 - 30 ]. The processes of study selection were summarized in the flow diagram (Figure 1 ).…”

Section: Resultsmentioning

confidence: 99%

Prognostic role of platelet to lymphocyte ratio in esophageal cancer: A meta-analysis

Zhao

Zhang

et al. 2017

Oncotarget

View full text Add to dashboard Cite

PurposeThe prognostic role of inflammation index like platelet to lymphocyte ratio (PLR) in esophageal cancer remains controversial. We evaluated the prognostic significance of PLR in esophageal cancer patients.MethodsWe searched databases to identify relevant literatures. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated. A meta-analysis was performed to evaluate the prognostic value of PLR in patients with esophageal cancer.ResultsA total of 6,699 patients from 16 studies (17 cohorts) were finally enrolled in the meta-analysis. The results demonstrate that the elevated PLR predicted poorer overall survival (OS) (HR: 1.389, 95% CI: 1.161-1.663) and disease-free survival (DFS) (HR: 1.404, 95% CI: 1.169-1.687) and cancer-specific survival (CSS) (HR: 1.686, 95% CI: 1.146-2.480) in patients with esophageal cancer. Subgroup analysis revealed that the elevated PLR was also associated with poor OS in esophageal cancer treated by surgery (HR: 1.492, 95%CI: 1.149-1.938, P<0.05) and mixed treatment (HR: 1.222, 95%CI: 1.009-1.479, P<0.05). In addition, PLR Cut-off value≤160 (HR: 1.484, 95%CI: 1.088-2.024, P<0.05) and PLR Cut-off value>160 (HR: 1.391, 95%CI: 1.161-1.666, P<0.05).ConclusionThis meta-analysis result suggested that PLR might be a significant predicative biomarker of poor prognosis for esophageal cancer patients.

show abstract

“…RDW is a measure of size variability[ 8 ] and heterogeneity of erythrocytes in the peripheral blood (i.e., anisocytosis) and is routinely measured in clinical practice as part of a complete blood count (CBC). More recent studies have investigated the role of RDW in patients with various cancer [ 9 – 11 ], and RDW was proved to be an independent prognosis factor in prostate cancer, chronic lymphocytic leukemia,esophageal cancer, hepatocellular carcinoma,breast cancer, diffuse large B-cell lymphoma,malignant mesothelioma,upper tract urothelial Carcinoma,myeloma and so on [ 8 – 16 ].We evaluated the OS and PFS by comparing RDW upon completion of therapy to the baseline at diagnosis. We found that patients whose RDW ≥ 15.5% upon completion of therapy experienced poorer prognosis.…”

Section: Discussionmentioning

confidence: 99%

“…Red blood cell distribution width (RDW) is a simple, inexpensive, routinely measured and automatically reported blood test parameter, which reflects the degree of anisocytosis of red blood cells in peripheral blood [ 5 – 7 ]. Previous studies in literature have shown that red blood cell distribution width are important prognostic marker in various solid cancers and hematology tumors [ 8 – 16 ]. RDW and its correlation with other prognostic factors can play an important role in risk stratification of MM patients [ 17 – 19 ].…”

Section: Introductionmentioning

confidence: 99%

Prognostic significance of the red blood cell distribution width that maintain at high level following completion of first line therapy in mutiple myeloma patients

Jin

Zhou

et al. 2018

Oncotarget

View full text Add to dashboard Cite

To investigate the prognostic value of the red blood cell distribution width(RDW) recovery from low levels at diagnosis after completion of first line therapy in mutiple myeloma (MM)patients,we enrolled 78 consecutive patients with MM and followed up from 2005 to 2016 in our hospital. The RDW was measured following completion of first-line therapy.The log-rank test, univariate analysis, and Cox regression analysis were used to evaluate the relationship between RDW and survival. We found that patients with an RDW ≥ 15.5% at diagnosis, as well as at completion of first-line therapy, had significantly lower progression-free survival (PFS) and overall survival(OS) rates than those with an RDW < 15.5%(P < 0.05).Patients with RDW that maintained more than 15.5% upon completion of therapy showed a shorter OS (P < 0.05) and PFS (P < 0.05) compared with patients with an RDW that decreased to a lower level.The multivariate analysis showed that RDW ≥ 15.5% after the completion of first-line therapy were an independent prognostic marker of poorer OS (P = 0.044) and PFS (P = 0.034). Therefore,we demonstrated that RDW at diagnosis, as well as at completion of first-line therapy is an independent predictor for mutiple myeloma patients.RDW maintained at high level, irrespective of whether RDW decreased to the cutoff value predicted an unfavorable prognosis in patients with MM.

show abstract

Preoperative blood-routine markers and prognosis of esophageal squamous cell carcinoma: The Fujian prospective investigation of cancer (FIESTA) study

Abstract: This prospective study was designed to investigate the prognosis of preoperative blood-routine markers for esophageal cancer mortality by using data from the ongoing

Cited by 25 publications

References 47 publications

Preoperative Metabolic Syndrome Is Predictive of Significant Gastric Cancer Mortality after Gastrectomy: The Fujian Prospective Investigation of Cancer (FIESTA) Study

Preoperative Metabolic Syndrome Is Predictive of Significant Gastric Cancer Mortality after Gastrectomy: The Fujian Prospective Investigation of Cancer (FIESTA) Study

Prognostic role of platelet to lymphocyte ratio in esophageal cancer: A meta-analysis

Prognostic significance of the red blood cell distribution width that maintain at high level following completion of first line therapy in mutiple myeloma patients

Contact Info

Product

Resources

About